MPI-ANGIO · Magnetic Particle Imaging for Safe Angiography
7РП — „Хора“ (Действия „Мария Кюри“)
- Период
- 2013-10-01 → 2017-09-30
- Финансиране от ЕС
- 100 000 €
- Участници
- 1
- Схема
- MC-CIG
Линиите свързват координатора с партньорите.
Накратко на български
Магнитният имиджинг (MPI) изследва нов начин за визуализиране на кръвоносните съдове чрез използване на железни наночастици. Това е важно, защото предлага по-безопасна алтернатива на йодните контрастни вещества, особено за пациенти с бъбречни заболявания.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Magnetic Particle Imaging for Safe Angiography
Project MPI-ANGIO (PCIG13-GA-2013-618834) considers several innovations in Magnetic Particle Imaging (MPI), a new imaging modality with the ideal image contrast for angiography that uses completely different hardware from X-ray, CT, or MRI. The contrast agent used in MPI, Super-Paramagnetic Iron Oxide nanoparticles (SPIOs), has been found to be extremely safe, even for chronic kidney disease (CKD) patients whose kidneys cannot safely excrete iodine contrast agents used during angiography today. Indeed, SPIOs are now EU approved to treat anemia in CKD patients. The MPI-ANGIO project proposes several innovations in MPI hardware, contrast agent and pulse sequences to significantly improve MPI’s spatial and temporal resolutions, making it competitive with CT Angiography. Several specific objectives were pursued during the two project periods regarding the development of MPI as a safe angiographic imaging modality. First, a relaxometer for characterizing magnetic nanoparticle properties was designed and built. Second, scientific teams and collaborations were established with material scientists with the purpose of developing and testing optimized MPI magnetic nanoparticles for improved resolution in MPI. Third, hardware design was performed for an in-house MPI scanner to enable detection of SPIOs at high temporal and spatial resolutions. Finally, rapid MPI pulse sequences and novel image reconstruction techniques were investigated to accelerate MPI scans without loss of spatial resolution. The results of the project are available on the project website: https://sites.google.com/site/mpiangiography. Given that currently only a handful of prototype small animal MPI scanners have been constructed worldwide, the results of the project are important in demonstrating the potential and performance limits of MPI angiography. The developed technology shows great promise as a noninvasive, nonionizing replacement for the millions of high-risk iodinated contrast studies performed annually. Moreover, the knowledge gained on hardware and pulse sequences for high spatio-temporal resolution MPI can render MPI a promising modality for the diagnosis of the top mortality diseases in Europe: strokes and other circulatory diseases (41% of all deaths) and cancer (25%).
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Magnetic Particle Imaging (MPI) is a new imaging modality with the ideal image contrast for angiography that uses completely different hardware from X-ray, CT, or MRI. MPI is now at an exciting stage of development similar to where MRI was in the early 1980s. Currently, there are no commercially available MPI scanners. Only a handful of prototype small animal MPI scanners have been constructed worldwide in research environments. Yet, there is already great promise for diagnostic application of MPI for the three top mortality diseases in the world: cardiovascular disease (25% of all deaths), cancer (23%), and stroke (5%). MPI angiography shows great promise as a noninvasive, non-ionizing replacement for the millions of high-risk iodinated contrast studies performed annually. The contrast agent used in MPI, Super-Paramagnetic Iron Oxide (SPIO) nanoparticles, has been found to be extremely safe, even for chronic kidney disease (CKD) patients whose kidneys cannot safely excrete iodine contrast agents of X-ray and CT angiography. Indeed, SPIOs are now EU approved to treat anemia in CKD patients. With this proposal, Dr. Saritas will begin development of Turkey’s first MPI laboratory, and transfer her MPI expertise acquired at University of California, Berkeley to the scientific community in Europe. MPI-ANGIO project proposes several innovations in MPI hardware, contrast agent and pulse sequences to improve MPI’s spatial and temporal resolutions, now ~2 mm pixels and 7-minute scan time, to a much sharper 300-micron resolution at 2-4 frames/second.
Оригинален текст от CORDIS (на английски).
Участници
- BILKENT UNIVERSITESI VAKIF · Bilkent AnkaraКоординаторТурция
Връзки
Данни: CORDIS, © Европейски съюз